Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
13.49
-0.05 (-0.37%)
Jan 17, 2025, 4:00 PM EST - Market closed
Inhibrx Biosciences Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Inhibrx Biosciences.
Analyst Consensus: Hold
Analyst Ratings
According to 1 stock analyst, the rating for INBX is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
---|---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
JMP Securities | JMP Securities | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Jul 23, 2024 |
JMP Securities | JMP Securities | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 23, 2024 |
JMP Securities | JMP Securities | Buy Reiterates $27 | Buy | Reiterates | $27 | +100.15% | Nov 20, 2023 |
JMP Securities | JMP Securities | Buy Maintains $35 → $27 | Buy | Maintains | $35 → $27 | +100.15% | Aug 23, 2023 |
JMP Securities | JMP Securities | Buy Reiterates $35 | Buy | Reiterates | $35 | +159.45% | May 10, 2023 |
Financial Forecast
Revenue This Year
102.00K
from 1.63M
Decreased by -93.76%
Revenue Next Year
n/a
from 102.00K
EPS This Year
113.83
EPS Next Year
-9.58
from 113.83
Revenue Forecast
Revenue | 2024 | 2025 |
---|---|---|
High | 105,000 | n/a |
Avg | 102,000 | n/a |
Low | 98,000 | n/a |
Revenue Growth
Revenue Growth | 2024 | 2025 |
---|---|---|
High | -93.6% | - |
Avg | -93.8% | - |
Low | -94.0% | - |
EPS Forecast
EPS | 2024 | 2025 |
---|---|---|
High | 124.23 | -7.05 |
Avg | 113.83 | -9.58 |
Low | 102.78 | -11.84 |
EPS Growth
EPS Growth | 2024 | 2025 |
---|---|---|
High | - | - |
Avg | - | - |
Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.